Circulating PD-1+ effector memory T cells predict anti-PD-1 efficacy in advanced gastric cancer
Kongcheng Wang, Jie Shao, Kai Xin, Lianru Zhang, Baorui Liu, Wenxiu Chen, Qin Liu · 2025
Read Circulating PD-1+ effector memory T cells predict anti-PD-1 efficacy in advanced gastric cancer by Kongcheng Wang, Jie Shao, Kai Xin, Lianru Zhang, Baorui Liu, Wenxiu Chen, Qin Liu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12727954.txt.
Description
Kongcheng Wang and six co-authors present a 2025 study on a blood test that may predict who benefits from immunotherapy in advanced stomach cancer. Checkpoint drugs help only a minority, and markers are urgently needed. Before treatment, the team measured how many of a patient's circulating memory T cells carried the PD-1 target protein, comparing fifty-four patients who later responded or did not.
Responders started with a higher share of such cells, and above a cutoff of about nine percent, patients progressed more slowly. The marker stayed independently protective after full adjustment. In the lab, blocking PD-1 woke these cells up, raising their killing power and signal output. The authors propose the simple blood measure as a guide for choosing chemo-immunotherapy. It could spare non-responders a treatment unlikely to help.
Catalog record
| CREATOR | Kongcheng Wang, Jie Shao, Kai Xin, Lianru Zhang, Baorui Liu, Wenxiu Chen, Qin Liu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |